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Objectives. We sought to compare efficacies of therapy for
ventricular tachyarrhythmias selected by programmed stimula-
tion using two different patient response efficacy criteria: <5
versus <16 repetitive ventricular responses.
Background. Therapy selection for ventricular tachyarrhyth-
mias by programmed stimulation requires definition of a patient
response that predicts long-term efficacy. Such definitions have
not been previously compared prospectively.
Methods. Patients with sustained ventricular tachyarrhythmias
were randomized to therapy selection using either the <5 or <16
repetitive response criterion of predicted effective therapy. The
primary end point was sudden death or recurrence of ventricular
tachyarrhythmia requiring intervention.
Results. Predicted effective drug therapy was found for 23 (34%)
of 68 patients randomized to the <5 criterion and 29 (36%) of 81
patients randomized to the <16 criterion (p 5 NS). Definition of
therapy required 3.0 6 1.6 drug trials (mean 6 SD) in patients
randomized to the <5 criterion and 2.9 6 1.8 trials in patients
randomized to the <16 criterion (p 5 NS). Patients randomized
to the <5 criterion had a lower 2-year probability of the primary
end point (0.20 6 0.05) than did patients randomized to the <16
criterion (0.33 6 0.05, one-tailed p 5 0.004). The advantage of the
<5 criterion was also seen in subgroup analyses involving patients
with and without an initial drug efficacy prediction.
Conclusions. The programmed stimulation approach to the
selection of antiarrhythmic therapy for ventricular tachyarrhyth-
mias using a patient response criterion of <5 repetitive ventric-
ular responses results in a lower probability of recurrence of
ventricular tachyarrhythmia than does use of a <16 repetitive
response criterion.
(J Am Coll Cardiol 1997;30:1346–53)
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To date, two approaches have been developed to select
individualized, prophylactic, antiarrhythmic drug therapy for
patients with a demonstrated propensity to sustained ventric-
ular tachycardia or ventricular fibrillation. Each approach
begins with demonstration of an index of ventricular electrical
instability in the antiarrhythmic drug-free state. The electro-
cardiographic monitoring approach (1–3) uses the patient’s
spontaneous ventricular arrhythmia as the baseline index of
electrical instability, whereas the electrophysiologic study ap-
proach (4–8) uses the induction of the patient’s ventricular
tachyarrhythmia by programmed electrical stimulation. There-
after, an antiarrhythmic drug regimen is predicted to be
effective for long-term use when suppression of the index of
electrical instability is demonstrated on that regimen. Both
approaches have been reported to identify a patient therapy
with an excellent long-term prognosis (1–11).
Two randomized clinical trials (12,13) have compared the
efficacies of individualized antiarrhythmic drug therapy for
patients with ventricular tachyarrhythmias selected by the
ECG monitoring approach with that selected by the electro-
physiologic study approach. The study of Mitchell et al. (14)
concluded that therapy selected by the electrophysiologic study
approach was superior to that selected by the ECG monitoring
approach, whereas the Electrophysiologic Study Versus Elec-
trocardiographic Monitoring (ESVEM) trial (15) concluded
that there was no significant difference between the two
approaches. The major difference between these two studies
was with respect to the outcome of therapy predicted to be
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effective by the electrophysiologic study approach. There was
no difference between these two studies with respect to the
outcome of therapy predicted to be effective by the ECG
monitoring approach.
Among the many procedural differences between the study
of Mitchell et al. (12) and the ESVEM trial (13) were
differences in the criteria defining predicted effective therapy
(16). Use of the electrophysiologic study approach requires a
criterion for the patient response to programmed stimulation
at the drug assessment study that predicts long-term efficacy. In
the study of Mitchell et al. (12,14), the maximal patient
response to programmed stimulation accepted was the induc-
tion of ,5 repetitive ventricular responses. In the ESVEM trial
(13,15), the maximal patient response accepted was the induc-
tion of ,16 repetitive ventricular responses. The rationale for
the latter, less stringent criterion includes a retrospective
evaluation (17) that concluded that the long-term efficacy of
therapy selected using a patient response cutoff of ,16 repet-
itive ventricular responses was comparable to that selected
using more stringent criteria. The ESVEM Investigators (18)
also published a retrospective evaluation of their own data
supporting this contention. To date, a prospective comparison
of these two patient response criteria has not been reported.
Accordingly, the purpose of the present study was to
compare the efficacy of individualized antiarrhythmic drug
therapy for patients with sustained ventricular tachyarrhyth-
mias selected by the electrophysiologic study approach using
the ,5 repetitive response criterion to that selected using the
,16 repetitive response criterion in a prospective, randomized
clinical trial.
Methods
Patients. A patient presenting to one of the five participat-
ing centers (Foothills Hospital, Calgary, Alberta; Calgary
General Hospital/Calgary District Hospitals, Calgary, Alberta;
Hamilton Civic Hospitals, Hamilton, Ontario; Victoria Gen-
eral Hospital, Halifax, Nova Scotia; or the Royal Alexandra
Hospital, Edmonton, Alberta) with symptomatic sustained
ventricular tachycardia or ventricular fibrillation in the absence
of a reversible or transient cause was eligible for participation
if the baseline antiarrhythmic drug-free programmed stimula-
tion study reproducibly induced the patient’s spontaneous
ventricular tachyarrhythmia and the physician then elected to
treat the patient with individualized antiarrhythmic drug ther-
apy selected by the electrophysiologic study approach. Patients
with a previously failed course of individualized antiarrhythmic
drug therapy selected by either the ECG monitoring approach
or the electrophysiologic study approach by virtue of ventric-
ular tachyarrhythmia recurrence were excluded. The protocol
and its informed consent were approved by the Institutional
Review Board of each participating site.
Patients were then randomized (1:1 in blocks of 10) to have
their long-term therapy selected using a patient response
criterion of ,5 repetitive ventricular responses or a patient
response criterion of ,16 repetitive ventricular responses. The
randomization process was stratified, in blocks of 10 patients,
for individual participating sites and for individual patient left
ventricular ejection fraction (#0.40 versus .0.40). The first
patient was randomized on August 19, 1986, and the last on
July 21, 1992. During that time, 192 patients met entry criteria
for the study, and 149 consented to participate.
Programmed stimulation protocol. The baseline antiar-
rhythmic drug-free programmed stimulation protocol included
single, double and triple extrastimuli with a duration of 2 ms
and an intensity twice the late diastolic stimulation threshold
applied after 8-beat trains of ventricular pacing at a cycle
length of 600, 500 and 400 ms at two right ventricular sites. The
sequence of programmed stimulation began at the right ven-
tricular apex using the single extrastimulus technique at pacing
cycle lengths of 600 ms, then 500 ms and then 400 ms. Two
extrastimuli were then utilized at each of the same pacing cycle
lengths, followed by three extrastimuli. Stimulus to stimulus
coupling intervals ,180 ms were not used. When necessary,
the entire stimulation protocol was repeated from the right
ventricular outflow tract. The end point of stimulation was
reproducible induction of a sustained ventricular tachyarrhyth-
mia, considered by the patient’s electrophysiologist to repre-
sent the clinical ventricular tachyarrhythmia. Recognizing that
a 12-lead ECG of a patient’s spontaneous ventricular tachyar-
rhythmia is often unavailable, this requirement translated into
accepting inducible sustained monomorphic ventricular tachy-
cardia as a significant arrhythmia worthy of suppression re-
gardless of the patient’s spontaneous tachyarrhythmia and
accepting inducible ventricular fibrillation as a significant
arrhythmia worthy of suppression only in patients presenting
with spontaneous ventricular fibrillation. Drug assessment
programmed stimulation studies were performed after at least
four half-lives of oral antiarrhythmic drug treatment. The
selection and sequence of specific antiarrhythmic drug trials
was left to the discretion of the patient’s electrophysiologist,
with the exception that amiodarone therapy was not permitted
at this stage. The drug assessment programmed stimulation
protocol was identical to that described for baseline studies but
was applied only to the right ventricular site that permitted
reproducible induction of ventricular tachyarrhythmia at the
baseline study, as in the study of Mitchell et al. (12) and the
ESVEM trial (13). If a predicted effective therapy was found,
the patient was discharged with that therapy. If no predicted
effective therapy could be found, the patient received alterna-
tive therapy.
Alternative therapies. Alternative therapy was individual-
ized by the patient’s electrophysiologist. Therapies permitted
Abbreviations and Acronyms
CI 5 confidence interval
ECG 5 electrocardiographic
ESVEM 5 Electrophysiologic Study Versus Electrocardiographic
Monitoring (trial)
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were empiric amiodarone therapy (19–21) without benefit of a
drug-assessment electrophysiologic study; an implantable
cardioverter-defibrillator (22–24); electrosurgery (25); or next-
best drug therapy. Next-best drug therapy was that which
permitted induction of ventricular tachycardia with a duration
exceeding the patient’s randomized assignment, had a cycle
length at least 100 ms longer than that induced at baseline, was
capable of being pace terminated when sustained and was
associated with no symptoms of hemodynamic compromise
(11).
Follow-up. Patients were evaluated clinically after 1, 2, 3, 6,
9, 12, 18 and 24 months. Thereafter, each patient was evalu-
ated on a yearly basis up to a common study termination date
of August 31, 1996. Patients who were intolerant of the drug
regimen predicted to be effective were readmitted for selection
of another predicted effective therapy or, if none could be
found, for alternative therapy. The primary end point of the
study was sudden cardiac death or recurrence of symptomatic
sustained ventricular tachyarrhythmia requiring external inter-
vention. Prespecified secondary end points were all-cause
mortality, cause-specific mortality and recurrence of any
sustained ventricular tachyarrhythmias (those requiring exter-
nal intervention plus those terminated by an implantable
cardioverter-defibrillator). Arrhythmias terminated by an im-
plantable cardioverter-defibrillator were included only if the
patient’s electrophysiologist concluded that the episode repre-
sented a true ventricular tachyarrhythmia after analysis of
patient symptoms and stored RR interval data.
Data analysis. Continuous variables are presented as mean
value 6 SD, and differences were evaluated by the Student
unpaired t test statistic, with significance ascribed to two-tailed
p values ,0.05. Discrete variables are presented as number
(percent), and differences were evaluated by the chi-square
statistic, with significance ascribed to two-tailed p values
,0.05. Event-free probabilities for the end points (6SEE)
were determined by the Kaplan-Meier method (26) and were
compared by the log-rank statistic (27), with significance
ascribed to one-tailed p values ,0.05.
For sample size determination, a one-tailed alpha of 0.05
and power of 80% were used. The estimated 2-year actuarial
probability of the primary outcome variable in the group
assigned to use of the ,16 repetitive response criterion was
45%, and the difference in event rate to be detected in the
other group was 20% less. To do so required a randomized
sample size of ;150 patients (28). This prospectively defined
one-tailed test was appropriate given the overwhelming im-
probability that use of the less stringent criterion for predicted
effective therapy could result in an improved efficacy.
Results
Patients. The demographic and clinical characteristics of
the 68 patients randomized to use of the ,5 repetitive
response criterion, the 81 patients randomized to use of the
,16 repetitive response criterion and the total 149 randomized
patients are presented in Table 1. Each group was dominated
by middle-aged men with coronary artery disease, remote
myocardial infarction, poor left ventricular function and pre-
sentation with hemodynamically significant ventricular tachy-
cardia or ventricular fibrillation. The distribution of these
characteristics was not significantly different between the two
randomized groups. The slight imbalance in the numbers of
patients randomized to each study group was the result of
stratification of the randomization process in relatively large
blocks such that it was possible to use only portions of several
randomization blocks. Nevertheless, the imbalance is not a
concern, for even the imbalanced distribution was randomly
determined.
Therapies. A predicted effective drug therapy was found
for 23 (34%) of the 68 patients randomized to use of the ,5
repetitive response criterion, and a predicted effective drug
therapy was found for 29 (36%) of the 81 patients randomized
to use of the ,16 repetitive response criterion (p 5 NS). To do
so required a mean of 3.0 6 1.6 antiarrhythmic drug trials in
patients randomized to use of the ,5 repetitive response
criterion and a mean of 2.9 6 1.8 antiarrhythmic drug trials in
patients randomized to use of the ,16 repetitive response
criterion (p 5 NS). The drug therapies predicted to be effective
in each group are presented in Table 2. There were no
statistically significant differences between the proportions of
patients in each group treated with specific predicted effective
drug regimens.
A predicted effective drug therapy was not found for 45
(66%) of the 68 patients randomized to use of the ,5
repetitive response criterion or for 52 (64%) of the 81 patients
randomized to use of the ,16 repetitive response criterion
(p 5 NS). These patients received alternative therapies, as
Table 1. Demographic and Clinical Characteristics of Study Cohort*
All
Randomized
Patients
(n 5 149)
Patients
Randomized to
,5 Rep Resp
Criterion
(n 5 68)
Patients
Randomized to
,16 Rep Resp
Criterion
(n 5 81)
Men 135 (91%) 62 (91%) 73 (90%)
Age (yr) 62 6 10 60 6 10 63 6 10
SHD
CAD/MI 133 (89%) 61 (90%) 72 (89%)
CM 12 (8%) 6 (9%) 6 (7%)
None 4 (3%) 1 (1%) 3 (4%)
Presentation
VF 32 (21%) 15 (22%) 17 (21%)
VT, hypotension 100 (67%) 46 (68%) 54 (67%)
Stable VT 17 (11%) 7 (10%) 10 (12%)
Inducible arrhythmia
Sustained VT 134 (90%) 58 (85%) 76 (94%)
VF 15 (10%) 10 (15%) 5 (6%)
LVEF (%) 0.33 6 0.12 0.32 6 0.13 0.34 6 0.11
*p 5 NS for all comparisons. Data presented are mean value 6 SD or
number (%) of patients. CAD 5 coronary artery disease; CM 5 cardiomyopa-
thy; LVEF 5 radionuclide left ventricular ejection fraction; MI 5 myocardial
infarction; Rep Resp 5 repetitive response; SHD 5 structural heart disease;
VF 5 ventricular fibrillation or ventricular flutter; VT 5 ventricular tachycardia.
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presented in Table 3. Five (83%) of the six patients random-
ized to use of the ,5 repetitive response criterion who
ultimately received an implantable cardioverter-defibrillator
also received concomitant antiarrhythmic drug therapy. Seven
(78%) of the nine patients randomized to use of the ,16
repetitive response criterion who ultimately received an im-
plantable cardioverter-defibrillator also received concomitant
antiarrhythmic drug therapy. There were no statistically signif-
icant differences between the proportions of patients receiving
each form of alternative therapy between the two randomized
groups.
Follow-up. The mean duration of patient follow-up was
5.0 6 2.5 years, with a minimal event-free follow-up period of
3.6 years.
The actuarial probabilities of sudden death or recurrence of
a symptomatic sustained ventricular tachyarrhythmia requiring
external intervention for the two randomized groups by inten-
tion to treat are displayed in Figure 1. Patients randomized to
use of the ,5 repetitive response criterion had lower follow-up
event probabilities than did patients randomized to use of the
,16 repetitive response criterion (0.09 6 0.03 vs. 0.28 6 0.05
after 1 year; 0.20 6 0.05 vs. 0.33 6 0.05 after 2 years; 0.23 6
0.05 vs. 0.41 6 0.06 after 3 years; 0.25 6 0.05 vs. 0.42 6 0.06
after 4 years; and 0.29 6 0.06 vs. 0.51 6 0.06 after 5 years,
respectively, p 5 0.004). Twenty (29%) of the 68 patients
randomized to the ,5 repetitive response criterion had a
primary event during follow-up. Forty-one (51%) of the 81
patients randomized to the ,16 repetitive response criterion
had a primary event during follow-up. The relative risk reduc-
tion accompanying use of the ,5 repetitive response criterion
was 42% (95% [CI] confidence interval 20% to 58%).
The advantage of the more stringent patient response
criterion was conserved in patients with and patients without a
drug efficacy prediction, as shown in Figures 2 and 3. However,
the reduction in sample size resulting from the subgroup
analyses reduced the level of statistical significance even
though the relative risk reductions were nearly identical.
Patients with a drug efficacy prediction after randomization to
use of the ,5 repetitive response criterion had lower follow-up
event probabilities than did patients with a drug efficacy
prediction after randomization to use of the ,16 repetitive
response criterion (0.13 6 0.07 vs. 0.32 6 0.09 after 1 year;
0.22 6 0.08 vs. 0.36 6 0.09 after 2 years; 0.30 6 0.09 vs. 0.48 6
0.10 after 3 years; 0.30 6 0.09 vs. 0.48 6 0.10 after 4 years; and
0.30 6 0.09 vs. 0.55 6 0.10 after 5 years, respectively, p 5 0.05).
Seven (30%) of the 23 patients with a drug-efficacy prediction
after randomization to use of the ,5 repetitive response
criterion had a primary event during follow-up. Fifteen (52%)
of the 29 patients with a drug efficacy prediction after random-
ization to use of the ,16 repetitive response criterion had a
primary event during follow-up. The observed risk reduction
accompanying use of the ,5 repetitive response criterion in
this subgroup analysis was 41% (95% CI 0% to 66%).
Similarly, patients without drug efficacy prediction using the
,5 repetitive response criterion who received alternative
therapy had lower follow-up event probabilities than did
patients without drug efficacy prediction using the ,16 repet-
itive response criterion who received alternative therapy
(0.07 6 0.04 vs. 0.25 6 0.06 after 1 year; 0.19 6 0.06 vs. 0.31 6
0.06 after 2 years; 0.19 6 0.06 vs. 0.38 6 0.07 after 3 years;
0.22 6 0.06 vs. 0.40 6 0.07 after 4 years; and 0.28 6 0.07 vs.
0.48 6 0.07 after 5 years, respectively, p 5 0.03). Thirteen
(29%) of the 45 patients without a drug efficacy prediction
after randomization to use of the ,5 repetitive response
criterion had a primary event during follow-up. Twenty-six
(50%) of the 52 patients without a drug efficacy prediction
after randomization to use of the ,16 repetitive response
criterion had a primary event during follow-up. The observed
risk reduction accompanying use of the ,16 repetitive re-
sponse criterion in this subgroup analysis was 42% (95% CI
13% to 62%).
The 2- and 5-year actuarial event probabilities for the
secondary analyses are presented in Table 4. Although patients
Table 3. Alternative Therapies*
Patients
Randomized to
,5 Rep Resp
Criterion
(n 5 45)
Patients
Randomized to
,16 Rep Resp
Criterion
(n 5 52)
Amiodarone 26 (58%) 29 (56%)
Next best drug 11 (24%) 13 (25%)
ICD 6 (13%) 9 (17%)
Electrosurgery 2 (4%) 1 (2%)
*p 5 NS for all comparisons. Data presented are number (%) of patients.
ICD 5 implantable cardioverter-defibrillator; Rep Resp 5 repetitive response.
Table 2. Predicted Effective Therapies*
Patients
Randomized to
,5 Rep Resp
(n 5 23)
Patients
Randomized to
,16 Rep Resp
(n 5 29)
Class Ia 13 (57%) 14 (48%)
Quin 9 (39%) 12 (41%)
Proc 4 (17%) 2 (7%)
Class Ic 3 (13%) 2 (7%)
PPF 3 (13%) 2 (7%)
Class III 3 (13%) 5 (17%)
Sot 2 (9%) 5 (17%)
Sem 1 (4%) 0
Combination 4 (17%) 5 (17%)
Quin/mex 1 (4%) 4 (14%)
Proc/mex 2 (9%) 0
Sot/mex 1 (4%) 0
PPF/mex 0 1 (3%)
Other 0 3 (10%)
Amil 0 1 (3%)
Dilt 0 1 (3%)
Meto 0 1 (3%)
*p 5 NS for all comparisons. Data presented are number (%) of patients.
Amil 5 amiloride; Dilt 5 diltiazem; Meto 5 metoprolol; Mex 5 mexiletine;
PPF 5 propafenone; Proc 5 procainamide; Quin 5 quinidine; Rep Resp 5
repetitive response; Sem 5 sematalide; Sot 5 sotalol.
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randomized to use of the ,5 repetitive response criterion had
lower follow-up probabilities of sustained ventricular tachyar-
rhythmias, this advantage did not appear to translate into a
lower follow-up probability of either sudden death or all-cause
mortality.
To evaluate potential mechanisms for these observations,
an efficacy analysis was performed by comparisons of the
subgroups of patients receiving antiarrhythmic drug therapy
that permitted induction of ,5, 5 to 15 and .15 repetitive
ventricular responses regardless of the original randomized
assignments (Fig. 4). The 2- and 5-year actuarial event proba-
bilities were 0.31 6 0.08 and 0.42 6 0.09 for therapy that
permitted induction of ,5 repetitive ventricular responses;
0.40 6 0.11 and 0.64 6 0.11 for therapy that permitted
induction of 5 to 15 repetitive ventricular responses; and
0.61 6 0.13 and 0.77 6 0.12 for therapy that permitted
induction of .15 repetitive ventricular responses.
Discussion
The major new information provided by the present investi-
gation is that application of the electrophysiologic study ap-
proach to the selection of antiarrhythmic drug therapy for
ventricular tachyarrhythmias using a patient response criterion
of ,5 repetitive ventricular responses results in a lower
probability of a ventricular tachyarrhythmia recurrence than
does use of a ,16 repetitive ventricular response criterion.
This advantage of the ,5 repetitive response criterion is found
in both patients with and without a drug efficacy prediction.
The reduction in ventricular tachyarrhythmia recurrence prob-
ability does not appear to translate into a lower follow-up
probability of either sudden death or all-cause mortality.
However, the confidence in such a no-difference statement
regarding these low probability events is very power limited.
To our knowledge, no other prospective studies have eval-
Figure 1. Actuarial probabilities of the primary end
point of sudden death or recurrence of a symptomatic
sustained ventricular tachyarrhythmia requiring external
intervention in the 68 patients randomized to use of the
,5 repetitive response criterion and the 81 patients
randomized to the ,16 repetitive response criterion.
Figure 2. Actuarial probabilities of the primary end
point of sudden death or recurrence of a symptomatic
sustained ventricular tachyarrhythmia requiring external
intervention in the 23 patients randomized to use of the
,5 repetitive response criterion with a drug efficacy
prediction and the 29 patients randomized to the ,16
repetitive response criterion with a drug efficacy predic-
tion.
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uated the relative advantages of various repetitive response
criteria. However, two retrospective reports have been pub-
lished. Swerdlow et al. (17) retrospectively analyzed their
experience with the electrophysiologic study approach after
178 consecutive patients had been treated with 255 long-term
trials (predominantly drug trials, but surgical trials were
heavily represented). Ninety-seven of these trials were with
treatment predicted to be effective using a #5 repetitive
response criterion. After failure to identify a predicted effec-
tive therapy using the #5 definition, an additional 23 trials
were predicted to be effective using a 6 to 10 repetitive
response criterion, and an additional 6 trials were predicted to
be effective using an 11 to 15 repetitive response criterion.
Actuarial analysis of antiarrhythmic efficacies on follow-up
(mean 7.8 months) comparing therapy predicted to be effective
by the #5, 6 to 10 and 11 to 15 repetitive response criteria
revealed no significant differences. More recently, the ESVEM
Investigators published a retrospective evaluation of their data
(18). They suggested that antiarrhythmic drug therapy pre-
dicted to be effective using a ,15 repetitive response criterion
provided as much protection (or in this case lack of protection)
as did drug therapy predicted to be effective using a ,5
repetitive response criterion or, indeed, as did therapy pre-
dicted to be effective using a ,2 repetitive response criterion.
Of course, the major problem with these two retrospective
assessments is that they represent observations of small sub-
groups that were distributed by factors other than by random-
ization. Unmeasured factors could have had a major impact on
the relative outcomes of the subgroups. Furthermore, the data
of these two retrospective studies cannot provide information
relative to the use of different patient response criteria for
those patients for whom no predicted effective therapy was
found. Accordingly, prospective data were needed. The results
of the present randomized study indicate that the use of less
stringent patient response criteria is associated with a reduc-
tion of the long-term efficacy of the therapy so chosen.
The mechanisms by which use of the more stringent patient
response criterion improves patient prognosis cannot be deter-
mined from the present study. Nevertheless, a hypothesis may
be surmised. The efficacy analysis of the results of the present
study suggest that the induction of ,5 repetitive ventricular
responses at the time of the drug assessment study predicts a
prognosis that is better than that associated with the induction
of 5 to 15 repetitive responses, which, in turn, predicts a
prognosis that is better than the induction of .15 repetitive
responses (Fig. 4). Accordingly, inclusion of the intermediate
risk group (5 to 15 repetitive responses) with either the high
risk group (.15 repetitive responses) or the low risk group (,5
repetitive responses) will profoundly effect their relative out-
comes. When the intermediate risk group is included with the
Figure 3. Actuarial probabilities of the primary end
point of sudden death or recurrence of a symptomatic
sustained ventricular tachyarrhythmia requiring exter-
nal intervention in the 45 patients without a predicted
effective therapy using the ,5 repetitive response
criterion and the 52 patients without a predicted
effective therapy using the ,16 repetitive response
criterion.
Table 4. Two- and Five-Year Event Probabilities by Outcome
Patients Randomized to ,5 Rep
Resp Criterion
Patients Randomized to ,16 Rep
Resp Criterion
RR
p
Value2-yr Probability 5-yr Probability 2-yr Probability 5-yr Probability
Sust VT/VF (ext) 0.20 6 0.05 0.29 6 0.06 0.33 6 0.05 0.51 6 0.06 42% 0.008
Sust VT/VF (any) 0.24 6 0.05 0.41 6 0.06 0.39 6 0.05 0.66 6 0.06 37% 0.003
Death 0.16 6 0.04 0.33 6 0.06 0.15 6 0.04 0.38 6 0.05 N/A NS
SCD 0.06 6 0.03 0.14 6 0.04 0.06 6 0.03 0.18 6 0.05 N/A NS
Data presented are mean value 6 SEE. RR 5 risk reduction accompanying use of the ,5 repetitive response (Rep Resp) criterion; SCD 5 sudden cardiac death;
Sust VT/VF (any) 5 any sustained ventricular tachycardia/ventricular fibrillation (VT/VF); Sust VT/VF (ext) 5 sustained VT/VF requiring external therapy.
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high risk group, the risk of the composite group formed will
be less than that of the original high risk group. When the
intermediate risk group is included with the low risk group,
the risk of the composite group will be greater than that of the
original low risk group. Thus, compared with a ,16 repetitive
response criterion, use of a ,5 repetitive response criterion
will improve the group prognosis of both those with and those
without an efficacy prediction. The improved prognosis of the
whole group whose therapy is selected by a criterion of ,5
repetitive responses results from providing patients with 5 to
15 repetitive responses and those with .15 repetitive re-
sponses an alternative therapy with an efficacy equivalent to
that of drug therapy permitting the induction of ,5 repetitive
responses.
Potential limitations. The results of the present investiga-
tion are relevant to the study cohort described and to use of the
programmed stimulation protocol described. Extrapolation to
other patient groups or to other programmed stimulation
protocols may not be appropriate. As was the practice during
the period of study enrollment, relatively few patients in this
study received therapy with class III antiarrhythmic drugs.
Although there is no suggestion that the study results may not
be extrapolated to patients receiving class III drugs, the
applicability of the results to this patient subgroup is not
certain. Those patients for whom no predicted effective anti-
arrhythmic drug therapy was found received alternative anti-
arrhythmic therapy. The use of these alternative antiarrhyth-
mic therapies was not defined by the protocol. Instead, the
choice was left to the discretion of the attending electrophysi-
ologist. Accordingly, the group treated with alternative antiar-
rhythmic therapy is discussed as a single entity because mean-
ingful comparisons of each of the forms of alternative
antiarrhythmic therapies cannot emerge from the present
study. Finally, this study also enrolled relatively few patients.
Nevertheless, to our knowledge, it represents the largest
prospective comparison of the procedural details of the elec-
trophysiologic study approach to the selection of antiarrhyth-
mic therapy for patients with ventricular tachyarrhythmias
reported to date.
Clinical implications. The results of the present investiga-
tion indicate that patients with a demonstrated propensity to
ventricular tachyarrhythmias whose therapy is selected using
the ,5 repetitive response criterion of predicted effective
therapy have a better prognosis than do patients whose therapy
is selected using the ,16 repetitive response criterion. Unex-
pectedly, the advantage of the more stringent criterion does
not decrease the probability of finding a predicted effective
antiarrhythmic therapy and does not extend the search for such
therapy. Accordingly, the present data recommend the general
use of the more stringent criterion of ,5 repetitive ventricular
responses. Furthermore, these data suggest that use of the less
stringent criterion of ,16 repetitive ventricular responses in
the electrophysiologic study limb of the ESVEM trial (14) may
explain, in part, the poor performance of therapy predicted to
be effective by the electrophysiologic study approach in that
study.
We are indebted to the technical and nursing staffs of the cardiology wards and
electrophysiologic study laboratories of the participating institutions and to our
cardiology colleagues for referring their patients for participation in this trial.
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